



AcceSS and Equity in Transplantation

Geographic variations in the epidemiology of kidney failure in New Zealand, 2006-2019

Johanna Birrell, Angela Webster, Nicholas Cross, Heather Dunckley, Ben Beaglehole, Ian Dittmer, John Irvine, Curtis Walker, Merryn Jones, Melanie Wyld, Kate Wyburn, Nicole De La Mata

Key findings:

1. The incidence of kidney failure and multimorbidity burden is highly variable across Aotearoa New Zealand
2. Living in a non-transplanting region was independently associated with disadvantage in accessing kidney transplantation
3. People of Māori or Pacific ethnicity were also independently disadvantaged in waitlisting and live donor transplantation.

Background:

- Transplantation is considered the ideal treatment for most people with kidney failure^{1,2}
- However, health system organisation may create inequities in access to best care
- ANZSN Key Performance Indicator (KPI):
 - Proportion of patients aged ≥ 2 years and < 65 years who are transplanted or “active” on the wait list **within 6 months** of starting kidney replacement therapy (KRT)³
- New Zealand (NZ) is currently undergoing major health reform.


Aim:

To describe the epidemiology of kidney failure in New Zealand, and assess the impact of residential location on access to kidney transplantation.

Health services research

Methods

Data linkage flowchart



Results



Cohort characteristics

Total number of people starting KRT in NZ, 2006-2019	7,704
Age at KRT start, median (IQR)	58 years (48-68)
Sex	
Male	4,633 (60%)
Female	3,071 (40%)
Ethnicity	
European	2,975 (39%)
Māori	2,380 (31%)
Pacific	1,605 (21%)
Asian	640 (8%)
Other ethnicity	74 (1%)
Rurality (GCH code)	
Urban (U1, U2)	6,271 (81%)
Rural (R1, R2, R3)	1,402 (18%)


Key findings:

1. The incidence of kidney failure and multimorbidity burden is highly variable across Aotearoa New Zealand


Trends in incidence of KRT in New Zealand, 2006-2019




Age-standardised
incidence of KRT,
2006-2019



Age-standardised
incidence of KRT,
2006-2019




Rurality of
patients
starting KRT




*Geographic Classification for Health
R1-R3 area, based on domicile



Age-standardised
incidence of KRT,
2006-2019




Rurality of
patients
starting KRT




Socio-economic
index of patients
starting KRT




Age-standardised incidence of KRT, 2006-2019





Socio-economic index of patients starting KRT



Rurality of patients starting KRT




Multimorbidity upon starting KRT




*Estimated 10-year survival $\leq 53\%$


Age-standardised incidence of KRT, 2006-2019




Rurality of patients starting KRT







Socio-economic index of patients starting KRT




Multimorbidity upon starting KRT




?



Proportion of people starting KRT with Charlson Comorbidity Index $\geq 2^*$: trend over study period (2006-2019)



Multimorbidity upon starting KRT







*Estimated 10-year survival of $\leq 53\%$

Key findings:


2. Living in a non-transplanting region was independently associated with disadvantage in accessing kidney transplantation

Region categories


-  *'Transplanting regions'* = District Health Boards (DHBs) containing a transplant unit, or adjacent to and staffed by a transplanting DHB throughout the study period.
-  *'Intermediate regions'* = DHBs with on-site nephrologists that refer patients directly to a transplant unit or received visiting transplant unit staff.
-  *'Remote regions'* = DHBs in which patients require referral to another DHB for nephrology review, followed by a second referral to a transplant unit.



Time between starting KRT and waitlisting (years), by region category in NZ, 2016-2019



Multiple logistic regression analysis: waitlisting or live donor transplantation by **6 months** after starting KRT



Note: ethnicity was also included in this model

Key findings:

3. People of Māori or Pacific ethnicity were also independently disadvantaged in waitlisting and live donor transplantation

Multiple logistic regression analysis: ethnicity comparison

Outcomes:

Waitlisting / live donor transplantation
by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral


Multiple logistic regression analysis: ethnicity comparison

Outcomes:


Waitlisting / live donor transplantation by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



* = reference category;
 OR = odds ratio




Multiple logistic regression analysis: ethnicity comparison

Outcomes:


Waitlisting / live donor transplantation by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



* = reference category;
 OR = odds ratio




Multiple logistic regression analysis: ethnicity comparison

Outcomes:

Waitlisting / live donor transplantation by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



Key findings:

1. The incidence of kidney failure and multimorbidity burden is highly variable across Aotearoa New Zealand
2. Living in a non-transplanting region was independently associated with disadvantage in accessing kidney transplantation
3. People of Māori or Pacific ethnicity were also independently disadvantaged in waitlisting and live donor transplantation.

References:

1. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. *PLoS One*. 2012; 7(1):e29591.
2. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes. *American Journal of Transplantation*. 2011; 11(10):2093–109.
3. ANZSN Key Performance Indicator (KPI) Working Group. A Nephrology KPI Program for Australia and Aotearoa New Zealand - Report of the Key Performance Indicator Working Group. Nov 2020. Available at: <https://nephrology.edu.au/int/anzsn/uploads/Reports/KPIWG%20Communicque%20-%2018%20November%202020.pdf>

Acknowledgements:

- **Research supervisors:** Dr Nicole De La Mata, Prof Angela Webster, Dr Nick Cross



- **The ASSET Team:**



- **The Ross Bailey Nephrology Trust**
- Human Research Council Activation Grant 2 HRC 20/1225 (ASSET Project)
- Prof Tim Driscoll, University of Sydney School of Public Health
- A/Prof James Stanley, Prof Diana Sarfati, A/Prof Jason Gurney - Multimorbidity project, University of Otago - Wellington (M3 Multimorbidity Index R code)
- Mr James Hedley, University of Sydney (adapted Charlson Comorbidity Index R Code)
- University of Otago – Rural-urban classification for NZ health research and policy

Thank you




Website:

<https://assetkidneyresearch.org>



[Home](#) [Data Platform](#) [Projects](#) [People](#) [Publications and Output](#) [Opportunities](#) [Related Links](#) [Contact Us](#)



Email:

info@assetkidneyresearch.org

Questions

